scholarly journals Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia

Nature ◽  
2014 ◽  
Vol 518 (7540) ◽  
pp. 552-555 ◽  
Author(s):  
Terrence N. Wong ◽  
Giridharan Ramsingh ◽  
Andrew L. Young ◽  
Christopher A. Miller ◽  
Waseem Touma ◽  
...  
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Tp53 Mutations ◽  
Origin And Evolution ◽  
Acute Myeloid

scholarly journals Beneficial role of increased FOXP3+ regulatory T-cells in acute myeloid leukaemia therapy response

2017 ◽  
Vol 182 (4) ◽  
pp. 581-583 ◽  
Author(s):  
Thomas Menter ◽  
Boris Kuzmanic ◽  
Christoph Bucher ◽  
Michael Medinger ◽  
Joerg Halter ◽  
...  
Keyword(s):  
T Cells ◽  
Regulatory T Cells ◽  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Therapy Response ◽  
Beneficial Role ◽  
Leukaemia Therapy ◽  
Acute Myeloid

scholarly journals Role of alternative polyadenylation dynamics in acute myeloid leukaemia at single-cell resolution

RNA Biology ◽  
2019 ◽  
Vol 16 (6) ◽  
pp. 785-797 ◽  
Author(s):  
Congting Ye ◽  
Qian Zhou ◽  
Yiling Hong ◽  
Qingshun Quinn Li
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Single Cell ◽  
Myeloid Leukaemia ◽  
Alternative Polyadenylation ◽  
Acute Myeloid

scholarly journals N6-Methyladenosine Role in Acute Myeloid Leukaemia

2018 ◽  
Vol 19 (8) ◽  
pp. 2345 ◽  
Author(s):  
Zaira Ianniello ◽  
Alessandro Fatica
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Cellular Differentiation ◽  
Normal Development ◽  
Rna Modifications ◽  
Deep Impact ◽  
Rna Molecules ◽  
Post Transcriptional Regulation ◽  
Acute Myeloid

We are currently assisting in the explosion of epitranscriptomics, which studies the functional role of chemical modifications into RNA molecules. Among more than 100 RNA modifications, the N6-methyladenosine (m6A), in particular, has attracted the interest of researchers all around the world. m6A is the most abundant internal chemical modification in mRNA, and it can control any aspect of mRNA post-transcriptional regulation. m6A is installed by “writers”, removed by “erasers”, and recognized by “readers”; thus, it can be compared to the reversible and dynamic epigenetic modifications in histones and DNA. Given its fundamental role in determining the way mRNAs are expressed, it comes as no surprise that alterations to m6A modifications have a deep impact in cell differentiation, normal development and human diseases. Here, we review the proteins involved in m6A modification in mammals, m6A role in gene expression and its contribution to cancer development. In particular, we will focus on acute myeloid leukaemia (AML), which provides an initial indication of how alteration in m6A modification can disrupt normal cellular differentiation and lead to cancer.

The role of intensive remission induction and consolidation therapy in patients with acute myeloid leukaemia

1987 ◽  
Vol 66 (1) ◽  
pp. 37-44 ◽  
Author(s):  
G. Tricot ◽  
M. A. Boogaerts ◽  
R. Vlietinck ◽  
M. P. Emonds ◽  
R. L. Verwilghen
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Remission Induction ◽  
Consolidation Therapy ◽  
Acute Myeloid

Association of MEG3 Hypermethylation and MiR-21 Upregulation with the Incidence in Iraqi Acute Myeloid Leukaemia Patients

2021 ◽  
Vol 19 (6) ◽  
pp. 122-128
Author(s):  
Noha Mohammed Saleh ◽  
Hameed Majeed Jasim
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Promoter Region ◽  
Hematologic Malignancy ◽  
Vital Role ◽  
Healthy Controls ◽  
Expression Levels ◽  
Elevated Expression ◽  
Acute Myeloid

Background: Acute myeloid leukaemia (AML) can be defined as a hematologic malignancy that distinguished by genetic defects and epigenetics alterations. LncRNA MEG3 was shown to play the role of tumour suppressor, and play a pivotal role in leukemogenesis, MEG3 hypermethylation has been reported to be related to different types of haematological malignancies. MIR-21 is regarded as a significant miRNA, it considered to play a vital role in AML progressions. Results: The levels of methylation in the MEG3 promoter region in AML patients were significantly increased than in healthy controls, as the MEG3 expression levels were significantly lowered (P ≤ 0.05) in AML patients in contrast with healthy controls. On the other hand, results showed elevated expression levels of miR-21 in AML patients compared with healthy controls. Conclusion: The present study indicates that the hypermethylation of MEG-3 promoter region could explain MEG-3 expression level loss. Our findings also revealed that the overexpression of miR-21 supports its function as an oncogene.

A Comprehensive Overview of the Role of Azacitidine in the Management of Myelodysplastic Syndromes and Acute Myeloid Leukaemia

2014 ◽  
Vol 10 (02) ◽  
pp. 89
Author(s):  
Hanmant V Barkate ◽  
Jaykumar J Sejpal ◽  
Yogesh R Belagali ◽  
◽  
◽  
...  
Keyword(s):  
Adverse Events ◽  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Myelodysplastic Syndromes ◽  
The Elderly ◽  
Best Supportive Care ◽  
Comparable Efficacy ◽  
Comprehensive Overview ◽  
Acute Myeloid

Myelodysplastic syndromes (MDS) are a heterogeneous group of haematological disorders marked by progressive cytopenias and risk of transformation to acute myeloid leukaemia (AML). Best supportive care (BSC) remains the mainstay of therapy. The pyrimidine analogue azacitidine was the first drug to demonstrate that a change in the natural history of MDS is possible and was the first chemotherapeutic agent approved by the US Food and Drug Administration for the treatment of MDS. Azacitidine, a hypomethylating agent, has shown to reduce proliferation and induce apoptosis of dysplastic cells. The Cancer and Leukemia Group B (CALGB) 9221 and AZA-001 trials demonstrated superiority of azacitidine over BSC and conventional care regimen, respectively. Various studies have demonstrated that azacitidine has better tolerability with comparable efficacy in terms of conventional therapy in older AML patients. Azacitidine is well tolerated even in the elderly patients. Cytopenias were the most commonly occurring haematological adverse events. Gastrointestinal adverse events (AEs) (e.g. nausea, vomiting and diarrhoea) and injection-site reactions were the most commonly occurring nonhaematological AEs. The review summarises the current role of azacitidine in the management of MDS and AML.

Sign in / Sign up

Export Citation Format

Share Document